These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8382875)

  • 1. Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. The Treatment IND Study Group.
    Werner BG; Snydman DR; Freeman R; Rohrer R; Tilney NL; Kirkman RL
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1441-3. PubMed ID: 8382875
    [No Abstract]   [Full Text] [Related]  

  • 2. Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease.
    Conti DJ; Freed BM; Lempert N
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1421-2. PubMed ID: 8382867
    [No Abstract]   [Full Text] [Related]  

  • 3. Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials.
    Snydman DR; Werner BG; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS; Strom TB; Carpenter CB
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1357-60. PubMed ID: 1846464
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial.
    Snydman DR; Werner BG; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS; Strom TB; Carpenter CB
    Transplant Proc; 1988 Dec; 20(6 Suppl 8):24-30. PubMed ID: 2849222
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
    Ahsan N; Holman MJ; Yang HC
    Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of infection and acute rejection after cytomegalovirus immune globulin prophylaxis in renal transplantation.
    Basadonna G; Feria A; Perez R; Klein H; Sturges M; Colquhoun S
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):52-3. PubMed ID: 7940976
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.
    Abraham KA; O'Kelly P; Spencer S; Hickey DP; Conlon PJ; Walshe JJ
    Ren Fail; 2008; 30(2):141-6. PubMed ID: 18300112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CMV hyperimmune globulin prophylaxis does not prevent CMV disease in CMV-negative renal transplant patients.
    Pakkala S; Salmela K; Lautenschlager I; Ahonen J; Häyry P
    Transplant Proc; 1992 Feb; 24(1):283-4. PubMed ID: 1311472
    [No Abstract]   [Full Text] [Related]  

  • 10. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
    Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A
    Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe graft rejection, increased immunosuppression, and active CMV infection in renal transplantation.
    von Müller L; Schliep C; Storck M; Hampl W; Schmid T; Abendroth D; Mertens T
    J Med Virol; 2006 Mar; 78(3):394-9. PubMed ID: 16419118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
    J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of cytomegalovirus disease in liver transplant patients treated prophylactically with combination cytomegalovirus hyperimmune globulin and ganciclovir.
    Prian GW; Koep LJ
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):54-5. PubMed ID: 7940977
    [No Abstract]   [Full Text] [Related]  

  • 14. Does CMV infection affect the outcome of renal allografts?
    Lautenschlager I; Salmela K; Häyry P
    Transplant Proc; 1992 Feb; 24(1):281-2. PubMed ID: 1311471
    [No Abstract]   [Full Text] [Related]  

  • 15. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival.
    McLaughlin K; Sandhu S; Wu C; Muirhead N; Hollomby D; Jevnikar A
    Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of the efficacy of cytomegalovirus immune globulin in the prophylaxis of CMV disease in renal transplant recipients.
    Snydman DR
    Transplant Proc; 1993 Oct; 25(5 Suppl 4):25-6. PubMed ID: 8212304
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
    Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
    Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of pretransplant cytomegalovirus infection on acute renal allograft rejection.
    Chen JH; Mao YY; He Q; Wu JY; Lv R
    Transplant Proc; 2005 Dec; 37(10):4203-7. PubMed ID: 16387078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group.
    Snydman DR; Werner BG; Dougherty NN; Griffith J; Rohrer RH; Freeman R; Jenkins R; Lewis WD; O'Rourke E
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):23-7. PubMed ID: 7940972
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.